Skip to content
Search

Latest Stories

Indian IT giant TCS sees profits slump, announces share buyback

India's largest software exporter Tata Consultancy Services announced a $2.18 billion share buyback plan on Wednesday, even as its profits fell amid the financial fallout from the coronavirus pandemic and an American legal case.

The country's second-most valuable firm by market size said net profit slumped by 7.1 percent to 74.75 billion rupees ($1.02 billion) for the July-September quarter compared to the previous corresponding period.


The company said it had also set aside 12.18 billion rupees under exceptional items for damages for a US litigation.

"The strong order book, a very robust deal pipeline, and continued market share gains give us confidence for the future," TCS chief executive Rajesh Gopinathan said in a statement.

Analysts said the share buyback was due to the ongoing legal tussle between its parent company Tata Sons and one of their oldest shareholders, The Shapoorji Pallonji Group.

The group has a 18.4 percent stake in Tata Sons but has indicated it wants to pull out of the salt-to-steel behemoth.

TCS was at the forefront of an IT boom that saw the country become a back office to the world as firms in developed nations subcontracted work, taking advantage of a skilled English-speaking workforce.

TCS earns more than 80 percent of its revenues from Western markets including Britain, the United States and Europe.

But the Covid-19 pandemic has battered demand for the firm's services in the financial and banking sectors.

Shares of TCS closed almost one percent higher on the Bombay Stock Exchange Sensex Index in Mumbai ahead of the results being released.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less